Evidence map›Paper›PMID 31110217›Full record

Trial reportLeukemia2019

CD22 CAR T-cell therapy in refractory or relapsed B acute lymphoblastic leukemia.

Jing Pan, Qing Niu, Biping Deng, Shuangyou Liu, Tong Wu, Zhiyong Gao, Zhaoli Liu, Yue Zhang, Xiaomin Qu, Yanlei Zhang and 18 more

Registry-linked trialAbstract readClinical Trial
PubMed Publisher
In one paragraph

Trial report in Leukemia, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06879340 (A Phase 1 Multicenter, Open Label Trial Evaluating the Safety and Efficacy of DuoCAR20.19.22-D95 in Adult Patients With Relapsed or Refractory B-cell Malignancies), which is not on this map. Cited by 146 papers, 11 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
146citing papers in PubMed, 11 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06879340 phase1recruitingnot on this mapstarted 2025, after this paper: background citation

A Phase 1 Multicenter, Open Label Trial Evaluating the Safety and Efficacy of DuoCAR20.19.22-D95 in Adult Patients With Relapsed or Refractory B-cell Malignancies

TypeinterventionalSponsorUniversity of Kansas Medical CenterRan2025 to 2040Enrolled54ConditionsB-Cell Non-Hodgkin Lymphoma, B-cell Acute Lymphoblastic LeukemiaArmsDuoCAR20.19.22-D95, Fludarabine (Conditional therapy), Cyclophosphamide (Conditional therapy)
3 · Its place in the literature

Who cites it

146 citing papers in PubMed, 11 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Pooled it
  11. Pooled it
  12. Trial
  13. Trial
  14. Trial
  15. Ruxolitinib mitigates steroid-refractory CRS during CAR T therapy.Journal of cellular and molecular medicine · 2021
    Trial
  16. Trial
  17. Trial
  18. Trial
  19. Review
  20. Review

86 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

28 authors.

Jing Pan *Department of Hematology, Beijing Boren Hospital, Beijing, 100070, China.
Qing Niu *State Key Laboratory of Experimental Hematology, National Clinical Research Center for Hematological disorders, Institute of Hematology and Hospital of Blood Diseases, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, 300020, China.
Biping DengCytology Laboratory, Beijing Boren Hospital, Beijing, 100070, China.
Shuangyou LiuDepartment of Hematology, Beijing Boren Hospital, Beijing, 100070, China.
Tong WuDepartment of Bone Marrow Transplantation, Beijing Boren Hospital, Beijing, 100070, China.
Zhiyong GaoDepartment of Bone Marrow Transplantation, Beijing Boren Hospital, Beijing, 100070, China.
Zhaoli LiuCytology Laboratory, Beijing Boren Hospital, Beijing, 100070, China.
Yue ZhangCytology Laboratory, Beijing Boren Hospital, Beijing, 100070, China.
Xiaomin QuCytology Laboratory, Beijing Boren Hospital, Beijing, 100070, China.
Yanlei ZhangClinical Translational Research Center, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai, 200433, China.
Shaohui LiuClinical Translational Research Center, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai, 200433, China.
Zhuojun LingDepartment of Hematology, Beijing Boren Hospital, Beijing, 100070, China.
Yuehui LinDepartment of Hematology, Beijing Boren Hospital, Beijing, 100070, China.
Yongqiang ZhaoDepartment of Bone Marrow Transplantation, Beijing Boren Hospital, Beijing, 100070, China.
Yanzhi SongDepartment of Bone Marrow Transplantation, Beijing Boren Hospital, Beijing, 100070, China.
Xiyou TanDepartment of Bone Marrow Transplantation, Beijing Boren Hospital, Beijing, 100070, China.
Yan ZhangDepartment of Bone Marrow Transplantation, Beijing Boren Hospital, Beijing, 100070, China.
Zhihui LiCytology Laboratory, Beijing Boren Hospital, Beijing, 100070, China.
Zhichao YinDepartment of Hematology, Beijing Boren Hospital, Beijing, 100070, China.
Bingzhen ChenMedical Laboratory, Beijing Boren Hospital, Beijing, 100070, China.
Xinjian YuMedical Laboratory, Beijing Boren Hospital, Beijing, 100070, China.
Ju YanMedical Laboratory, Beijing Boren Hospital, Beijing, 100070, China.
Qinlong ZhengMedical Laboratory, Beijing Boren Hospital, Beijing, 100070, China.
Xuan ZhouGaobo Healthcare Group, Beijing, China.
Jin GaoGaobo Healthcare Group, Beijing, China.
Alex H Chang *Clinical Translational Research Center, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai, 200433, China. alexhchang@yahoo.com.
Xiaoming Feng *State Key Laboratory of Experimental Hematology, National Clinical Research Center for Hematological disorders, Institute of Hematology and Hospital of Blood Diseases, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, 300020, China. fengxiaoming@ihcams.ac.cn.
Chunrong Tong *Department of Hematology, Beijing Boren Hospital, Beijing, 100070, China. tongcr@borenhospital.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Despite worldwide promising clinical outcome of CD19 CAR-T therapy, relapse after this therapy is associated with poor prognosis and has become an urgent problem to be solved. We conducted a CD22 CAR T-cell therapy in 34 relapsed or refractory (r/r) B-ALL pediatric and adult patients who failed from previous CD19 CAR T-cell therapy. Complete remission (CR) or CR with incomplete count recovery (CRi) was achieved in 24 of 30 patients (80%) that could be evaluated on day 30 after infusion, which accounted for 70.5% of all 34 enrolled patients. Most patients only experienced mild cytokine-release syndrome and neurotoxicity. Seven CR patients received no further treatment, and 3 of them remained in remission at 6, 6.6, and 14 months after infusion. Eleven CR patients were promptly bridged to transplantation, and 8 of them remained in remission at 4.6 to 13.3 months after transplantation, resulted in 1-year leukemia-free survival rate of 71.6% (95% CI, 44.2-99.0). CD22 antigen loss or mutation was not observed to be associated with relapsed patients. Our study demonstrated that our CD22 CAR T-cells was highly effective in inducing remission in r/r B-ALL patients, and also provided a precious window for subsequent transplantation to achieve durable remission.

Indexed as

Immunotherapy, AdoptiveAdolescentAdultAntigens, NeoplasmBiopsyChildChild, PreschoolCombined Modality TherapyCytokinesCytotoxicity, ImmunologicDisease ManagementFemaleFollow-Up StudiesHumansInfantMaleAntigens, NeoplasmCD22 protein, humanCytokinesReceptors, Antigen, T-CellReceptors, Chimeric AntigenSialic Acid Binding Ig-like Lectin 2

Identifiers

PMID31110217

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.